Renee Cowan1, Silvana Pedra Nobre1, Nisha Pradhan2, Maya Yasukawa1, Qin C Zhou3, Alexia Iasonos3, Robert A Soslow4, Angela G Arnold2, Magan Trottier2, Amanda Catchings2, Kara Long Roche5, Ginger Gardner5, Mark Robson6, Nadeem R Abu Rustum5, Carol Aghajanian7, Karen Cadoo8. 1. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College of Cornell University, New York, NY, USA. 5. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College of Cornell University, New York, NY, USA. 6. Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College of Cornell University, New York, NY, USA; Robert and Kate Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7. Weill Medical College of Cornell University, New York, NY, USA; Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8. Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College of Cornell University, New York, NY, USA; Robert and Kate Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; HOPe Directorate, St. James's Hospital, Dublin, Ireland. Electronic address: kcadoo@stjames.ie.
Abstract
OBJECTIVE: Prior data suggested that women with incidentally detected occult invasive ovarian cancer (OIOC) at the time of risk-reducing salpingo-oophorectomy (RRSO) for BRCA mutation may have poorer prognoses than would be expected based on disease stage. We sought to evaluate prevalence and outcomes of patients with OIOC in a tertiary referral center. METHODS: Patients with BRCA mutation undergoing RRSO from 01/2005 to 05/2017 were identified, and their records reviewed. Women with incidentally detected OIOC were included; those with clinical features raising preoperative suspicion for malignancy were excluded. RESULTS: 548 patients with BRCA mutation who underwent RRSO were identified. 26 (4.7%) had an OIOC (median age 55 years; range 42-75); 15(58%) patients, BRCA1; 9(34%), BRCA2; 2(8%) had a mutation in both genes. All OIOCs were high-grade serous: 10 (38%) Stage I; 8 (31%) Stage II; 8(31%) Stage III. 24(92%) patients received adjuvant platinum/taxane therapy. Of Stage III patients, 4 (50%) were identified intraoperatively; the remaining 4 (50%) had microscopic nodal disease on final pathology only. At median follow-up of 67.3 months (28-166) no Stage I patients have recurred; 2 Stage II and 6 Stage III patients recurred. 5-year progression-free survival (PFS) was 72% (95%CI, 50.2-85.7%); median PFS for the cohort was 129 months (95%CI, 75.3-not estimable). 5-year disease-specific survival (DSS) was 96% (95%CI, 76-99%); median DSS not reached. CONCLUSION: Consistent with prior reports, almost 5% of patients had an OIOC at RRSO. The majority with early-stage disease had excellent PFS and DSS outcomes, as would be expected based on disease stage.
OBJECTIVE: Prior data suggested that women with incidentally detected occult invasive ovarian cancer (OIOC) at the time of risk-reducing salpingo-oophorectomy (RRSO) for BRCA mutation may have poorer prognoses than would be expected based on disease stage. We sought to evaluate prevalence and outcomes of patients with OIOC in a tertiary referral center. METHODS: Patients with BRCA mutation undergoing RRSO from 01/2005 to 05/2017 were identified, and their records reviewed. Women with incidentally detected OIOC were included; those with clinical features raising preoperative suspicion for malignancy were excluded. RESULTS: 548 patients with BRCA mutation who underwent RRSO were identified. 26 (4.7%) had an OIOC (median age 55 years; range 42-75); 15(58%) patients, BRCA1; 9(34%), BRCA2; 2(8%) had a mutation in both genes. All OIOCs were high-grade serous: 10 (38%) Stage I; 8 (31%) Stage II; 8(31%) Stage III. 24(92%) patients received adjuvant platinum/taxane therapy. Of Stage III patients, 4 (50%) were identified intraoperatively; the remaining 4 (50%) had microscopic nodal disease on final pathology only. At median follow-up of 67.3 months (28-166) no Stage I patients have recurred; 2 Stage II and 6 Stage III patients recurred. 5-year progression-free survival (PFS) was 72% (95%CI, 50.2-85.7%); median PFS for the cohort was 129 months (95%CI, 75.3-not estimable). 5-year disease-specific survival (DSS) was 96% (95%CI, 76-99%); median DSS not reached. CONCLUSION: Consistent with prior reports, almost 5% of patients had an OIOC at RRSO. The majority with early-stage disease had excellent PFS and DSS outcomes, as would be expected based on disease stage.
Authors: Mary B Daly; Robert Pilarski; Michael Berry; Saundra S Buys; Meagan Farmer; Susan Friedman; Judy E Garber; Noah D Kauff; Seema Khan; Catherine Klein; Wendy Kohlmann; Allison Kurian; Jennifer K Litton; Lisa Madlensky; Sofia D Merajver; Kenneth Offit; Tuya Pal; Gwen Reiser; Kristen Mahoney Shannon; Elizabeth Swisher; Shaveta Vinayak; Nicoleta C Voian; Jeffrey N Weitzel; Myra J Wick; Georgia L Wiesner; Mary Dwyer; Susan Darlow Journal: J Natl Compr Canc Netw Date: 2017-01 Impact factor: 11.908
Authors: Michael A Bookman; C Blake Gilks; Elise C Kohn; Karen O Kaplan; David Huntsman; Carol Aghajanian; Michael J Birrer; Jonathan A Ledermann; Amit M Oza; Kenneth D Swenerton Journal: J Natl Cancer Inst Date: 2014-03-13 Impact factor: 13.506
Authors: Robert J Morgan; Deborah K Armstrong; Ronald D Alvarez; Jamie N Bakkum-Gamez; Kian Behbakht; Lee-May Chen; Larry Copeland; Marta Ann Crispens; Maria DeRosa; Oliver Dorigo; David M Gershenson; Heidi J Gray; Ardeshir Hakam; Laura J Havrilesky; Carolyn Johnston; Shashikant Lele; Lainie Martin; Ursula A Matulonis; David M O'Malley; Richard T Penson; Sanja Percac-Lima; Mario Pineda; Steven C Plaxe; Matthew A Powell; Elena Ratner; Steven W Remmenga; Peter G Rose; Paul Sabbatini; Joseph T Santoso; Theresa L Werner; Jennifer Burns; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2016-09 Impact factor: 11.908
Authors: Christopher P Childers; Kimberly K Childers; Melinda Maggard-Gibbons; James Macinko Journal: J Clin Oncol Date: 2017-08-18 Impact factor: 44.544
Authors: Edith A Sijmons; Marieke A L van Lankveld; Petronella O Witteveen; Petra H M Peeters; Veronica C M Koot; Jules Schagen van Leeuwen Journal: Eur J Obstet Gynecol Reprod Biol Date: 2006-05-16 Impact factor: 2.435
Authors: Timothy R Rebbeck; Henry T Lynch; Susan L Neuhausen; Steven A Narod; Laura Van't Veer; Judy E Garber; Gareth Evans; Claudine Isaacs; Mary B Daly; Ellen Matloff; Olufunmilayo I Olopade; Barbara L Weber Journal: N Engl J Med Date: 2002-05-20 Impact factor: 91.245
Authors: Michael J Callahan; Christopher P Crum; Fabiola Medeiros; David W Kindelberger; Julia A Elvin; Judy E Garber; Colleen M Feltmate; Ross S Berkowitz; Michael G Muto Journal: J Clin Oncol Date: 2007-09-01 Impact factor: 44.544
Authors: Jennifer L Caswell-Jin; Anjali D Zimmer; Will Stedden; Kerry E Kingham; Alicia Y Zhou; Allison W Kurian Journal: J Natl Cancer Inst Date: 2019-01-01 Impact factor: 13.506